Lifeward to Open Q2 2026 Clinic Days at Shirley Ryan AbilityLab for ReWalk Exoskeleton Trials
Lifeward will launch dedicated clinic days in Q2 2026 at Shirley Ryan AbilityLab’s Chicago campus to accelerate evaluation and trial of its FDA-cleared ReWalk Personal Exoskeleton for individuals with spinal cord injury. Shirley Ryan AbilityLab—ranked No.1 in U.S. rehabilitation for 35 consecutive years—will manage clinical evaluation, training and support.
1. Collaboration Launch Details
Lifeward and Shirley Ryan AbilityLab will initiate dedicated clinic days in Q2 2026 at the Chicago campus to offer hands-on evaluation and trial of the ReWalk Personal Exoskeleton. These sessions aim to streamline the pathway from patient assessment to real-world use for individuals living with spinal cord injuries.
2. Clinical Evaluation and Training
Shirley Ryan AbilityLab, ranked the top rehabilitation hospital in the U.S. for 35 consecutive years, will oversee clinical evaluations, device training and ongoing patient support. The hospital’s experts will guide trial participants through functional ambulation exercises and monitor outcomes to ensure safe and effective use.
3. ReWalk Exoskeleton Overview
The ReWalk Personal Exoskeleton is an FDA-cleared wearable robotic system that enables users with spinal cord injuries to stand, walk and navigate stairs and curbs. Clinical studies link powered exoskeleton use to improved ambulation, better health outcomes and enhanced quality of life.
4. Strategic Impact for Lifeward
This marks Lifeward’s first formal collaboration with a leading rehabilitation research hospital, potentially boosting market adoption of its exoskeleton technology. By embedding ReWalk trials within a top clinical ecosystem, Lifeward expects to accelerate device uptake and strengthen its position in the rehabilitation market.